A Phase 1 Trial of the Safety, Tolerability, and Immunogenicity of BLB-201 Vaccine in Healthy Young Adults and Older Adults

Status: Completed
Location: See all (2) locations...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 1
SUMMARY

This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15 healthy young adults ages 18-59 years, and 15 older adults ages 60-75 years.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: Accepts Healthy Volunteers
View:

• Provide informed consent prior to initiation of any trial procedures.

• Be able to understand and agrees to comply with planned trial procedures and be available for all trial visits and phone calls.

• Healthy male or non-pregnant female, between 18 and 59 years of age (Group 1) or between60 and 75 years of age (Group 2), inclusive, at time of trial vaccination.

• Women of childbearing potential must agree to use or have practiced true abstinence or use at least one acceptable primary form of contraception. Note: These criteria are applicable to females in a heterosexual relationship and child-bearing potential (i.e., the criteria do not apply to subjects in a same sex relationship).

• Women of childbearing potential must have a negative urine or serum pregnancy test within 24 hours prior to each vaccination.

• Male subjects of childbearing potential* must use condoms to ensure effective contraception with a female partner of childbearing potential from vaccination until 90 days after vaccination. Such female partners must also use an acceptable form of primary contraception as described under inclusion criterion #4. If barrier methods are to be used, then double barrier methods of protection are required, i.e. male condom, in combination with a cap, diaphragm, or sponge with spermicide. *Biological males who are post-pubertal and considered fertile until permanently sterile by bilateral orchiectomy or vasectomy.

• Male subjects agree to refrain from sperm donation from the time of vaccination until 90 days after vaccination.

• Female subjects agree to refrain from egg donation from time of vaccination until 90 days after vaccination.

• In good health.

Locations
United States
Ohio
Cincinnati Children's Hospital Medical Center
Cincinnati
South Carolina
Coastal Carolina Research Center
North Charleston
Time Frame
Start Date: July 20, 2022
Completion Date: December 5, 2022
Participants
Target number of participants: 30
Treatments
Experimental: Group 1, young adult cohort (age 18-59)
BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
Experimental: Group 2, older adult cohort (age 60-75)
BLB-201 administered as a single dose of 10^7.5 PFU by intranasal route on Day 1
Sponsors
Leads: Blue Lake Biotechnology Inc.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials